Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce
the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with
breast cancer that can be removed by surgery.